Campbell & Co Investment Adviser’s Acadia Pharmaceuticals ACAD Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11M	Buy	+83,341	New	+$1.83M	0.11%	304
2025 Q4	–	Sell	-39,286	Closed	-$838K	–	1099
2025 Q3	$838K	Buy	+39,286	New	+$929K	0.06%	490
2024 Q3	–	Sell	-36,122	Closed	-$587K	–	1058
2024 Q2	$587K	Buy	+36,122	New	+$583K	0.05%	593
2024 Q1	–	Sell	-67,342	Closed	-$2.11M	–	1070
2023 Q4	$2.11M	Buy	+67,342	New	+$1.61M	0.19%	119
2023 Q3	–	Sell	-15,619	Closed	-$374K	–	907
2023 Q2	$374K	Buy	+15,619	New	+$347K	0.07%	566
2021 Q4	–	Sell	-15,250	Closed	-$253K	–	596
2021 Q3	$253K	Buy	+15,250	New	+$294K	0.08%	434
2020 Q3	–	Sell	-4,581	Closed	-$222K	–	371
2020 Q2	$222K	Buy	+4,581	New	+$220K	0.28%	185
2020 Q1	–	Sell	-5,040	Closed	-$216K	–	22
2019 Q4	$216K	Sell	5,040 -11,153	-69%	-$485K	0.07%	558
2019 Q3	$583K	Buy	+16,193	New	+$491K	0.22%	136
2017 Q3	–	Sell	-9,817	Closed	-$274K	–	337
2017 Q2	$274K	Buy	+9,817	New	+$293K	0.25%	163

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Campbell & Co Investment Adviser's ACAD Position: Q2 2026 in Review

Campbell & Co Investment Adviser opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 83,341 shares worth $2.11M. The stake represents 0.11% of the portfolio and ranks #304 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in ACAD as recently as Q3 2025.

Campbell & Co Investment Adviser first reported a position in ACAD in Q2 2017 and has held it in 10 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Campbell & Co Investment Adviser held 83,341 shares of Acadia Pharmaceuticals worth $2.11M as of Q2 2026.
Acadia Pharmaceuticals was a new Campbell & Co Investment Adviser position in Q2 2026.
Acadia Pharmaceuticals made up 0.11% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #304 holding.
Campbell & Co Investment Adviser first reported a position in Acadia Pharmaceuticals in Q2 2017 and has held it in 10 quarters since.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.